Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/1549
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | DIAS, V. V. | - |
dc.contributor.author | BALANZA-MARTINEZ, V. | - |
dc.contributor.author | SOEIRO-DE-SOUZA, M. G. | - |
dc.contributor.author | MORENO, R. A. | - |
dc.contributor.author | FIGUEIRA, M. L. | - |
dc.contributor.author | MACHADO-VIEIRA, R. | - |
dc.contributor.author | VIETA, E. | - |
dc.date.accessioned | 2013-07-30T17:53:33Z | - |
dc.date.available | 2013-07-30T17:53:33Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | ACTA PSYCHIATRICA SCANDINAVICA, v.126, n.5, p.315-331, 2012 | - |
dc.identifier.issn | 0001-690X | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/1549 | - |
dc.description.abstract | Dias VV, Balanza-Martinez V, Soeiro-de-Souza MG, Moreno RA, Figueira ML, Machado-Vieira R, Vieta E. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Objective: Historically, pharmacological treatments for bipolar disorders (BD) have been associated with neurocognitive side-effects. We reviewed studies which assessed the impact of several psychopharmacological drugs on the neurocognitive function of BD patients. Method: The PubMed database was searched for studies published between January 1980 and February 2011, using the following terms: bipolar, bipolar disorder, mania, manic episode, or bipolar depression, cross-referenced with cognitive, neurocognitive, or neuropsychological, cross-referenced with treatment. Results: Despite methodological flaws in the older studies and insufficient research concerning the newer agents, some consistent findings emerged from the review; lithium appears to have definite, yet subtle, negative effects on psychomotor speed and verbal memory. Among the newer anticonvulsants, lamotrigine appears to have a better cognitive profile than carbamazepine, valproate, topiramate, and zonisamide. More long-term studies are needed to better understand the impact of atypical antipsychotics on BD patients neurocognitive functioning, both in monotherapy and in association with other drugs. Other agents, like antidepressants and cognitive enhancers, have not been adequately studied in BD so far. Conclusion: Pharmacotherapies for BD should be chosen to minimize neurocognitive side-effects, which may already be compromised by the disease process itself. Neurocognitive evaluation should be considered in BD patients to better evaluate treatment impact on neurocognition. A comprehensive neuropsychological evaluation also addressing potential variables and key aspects such as more severe cognitive deficits, comorbidities, differential diagnosis, and evaluation of multiple cognitive domains in longitudinal follow-up studies are warranted. | - |
dc.description.sponsorship | Lundbeck | - |
dc.description.sponsorship | Sanofi-Aventis | - |
dc.description.sponsorship | AstraZeneca | - |
dc.description.sponsorship | Bristol-Myers Squibb | - |
dc.description.sponsorship | Fundacion Alicia Koplowitz | - |
dc.description.sponsorship | Almirall | - |
dc.description.sponsorship | Grunenthal | - |
dc.description.sponsorship | Janssen | - |
dc.description.sponsorship | Juste | - |
dc.description.sponsorship | Pfizer | - |
dc.description.sponsorship | Eli Lilly | - |
dc.description.sponsorship | Forest Research Institute | - |
dc.description.sponsorship | Geodon Richter | - |
dc.description.sponsorship | Glaxo-Smith-Kline | - |
dc.description.sponsorship | Janssen-Cilag | - |
dc.description.sponsorship | Jazz | - |
dc.description.sponsorship | Johnson Johnson | - |
dc.description.sponsorship | Merck | - |
dc.description.sponsorship | Novartis | - |
dc.description.sponsorship | Organon | - |
dc.description.sponsorship | Otsuka | - |
dc.description.sponsorship | Pierre-Fabre | - |
dc.description.sponsorship | Qualigen | - |
dc.description.sponsorship | Servier | - |
dc.description.sponsorship | Shering-Plough | - |
dc.description.sponsorship | Solvay | - |
dc.description.sponsorship | Takeda | - |
dc.description.sponsorship | Spanish Ministry of Science and Innovation (CIBERSAM) | - |
dc.description.sponsorship | Seventh European Framework Programme (ENBREC) | - |
dc.description.sponsorship | Stanley Medical Research Institute | - |
dc.description.sponsorship | United Biosource Corporation | - |
dc.description.sponsorship | Wyeth | - |
dc.language.iso | eng | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.relation.ispartof | Acta Psychiatrica Scandinavica | - |
dc.rights | restrictedAccess | - |
dc.subject | bipolar disorder | - |
dc.subject | depression | - |
dc.subject | anticonvulsants | - |
dc.subject | antipsychotics | - |
dc.subject | lithium | - |
dc.subject | antidepressants | - |
dc.subject | memory | - |
dc.subject | cognition | - |
dc.subject | neuroprotection | - |
dc.subject | polypharmacy | - |
dc.subject | neurocognition | - |
dc.subject | neuropsychological | - |
dc.subject.other | term lithium treatment | - |
dc.subject.other | controlled 18-month trial | - |
dc.subject.other | i disorder | - |
dc.subject.other | healthy-volunteers | - |
dc.subject.other | double-blind | - |
dc.subject.other | neurocognitive impairment | - |
dc.subject.other | maintenance treatment | - |
dc.subject.other | follow-up | - |
dc.subject.other | psychomotor performance | - |
dc.subject.other | antiepileptic drugs | - |
dc.title | Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview | - |
dc.type | article | - |
dc.rights.holder | Copyright WILEY-BLACKWELL | - |
dc.identifier.doi | 10.1111/j.1600-0447.2012.01910.x | - |
dc.identifier.pmid | 22881296 | - |
dc.subject.wos | Psychiatry | - |
dc.type.category | review | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | DIAS, V. V.:Univ Lisbon FMUL, Hosp Santa Maria, Fac Med, Bipolar Disorder Res Program, P-1649035 Lisbon, Portugal | - |
hcfmusp.author.external | BALANZA-MARTINEZ, V.:Univ Valencia, Univ Hosp Doctor Peset, Valencia, Spain; Univ Valencia, Sect Psychiat, Valencia, Spain; Inst Salud Carlos III, CIBER Salud Mental CIBERSAM, Madrid, Spain | - |
hcfmusp.author.external | SOEIRO-DE-SOUZA, M. G.:Univ Sao Paulo, Mood Disorders Unit, BR-05508 Sao Paulo, Brazil | - |
hcfmusp.author.external | MORENO, R. A.:Univ Sao Paulo, Mood Disorders Unit, BR-05508 Sao Paulo, Brazil | - |
hcfmusp.author.external | FIGUEIRA, M. L.:Univ Lisbon FMUL, Hosp Santa Maria, Fac Med, Bipolar Disorder Res Program, P-1649035 Lisbon, Portugal | - |
hcfmusp.author.external | VIETA, E.:Univ Barcelona, Univ Hosp Clin, Bipolar Disorders Program, CIBERSAM,IDIBAPS,Clin Inst Neurosci, Barcelona, Spain | - |
hcfmusp.description.beginpage | 315 | - |
hcfmusp.description.endpage | 331 | - |
hcfmusp.description.issue | 5 | - |
hcfmusp.description.volume | 126 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84867455604 | - |
hcfmusp.origem.id | WOS:000309714200002 | - |
hcfmusp.publisher.city | HOBOKEN | - |
hcfmusp.publisher.country | USA | - |
hcfmusp.relation.reference | Advokat C, 2010, NEUROSCI BIOBEHAV R, V34, P1256, DOI 10.1016/j.neubiorev.2010.03.006 | - |
hcfmusp.relation.reference | Alda M, 2009, CAN J PSYCHIAT, V54, P719 | - |
hcfmusp.relation.reference | Aldenkamp AP, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s4.3.x | - |
hcfmusp.relation.reference | Aldenkamp AP, 2002, EPILEPSIA, V43, P19, DOI 10.1046/j.1528-1157.2002.29201.x | - |
hcfmusp.relation.reference | Andreazza AC, 2008, J PSYCHIATR NEUROSCI, V33, P516 | - |
hcfmusp.relation.reference | Andreazza AC, 2008, J AFFECT DISORDERS, V111, P135, DOI 10.1016/j.jad.2008.04.013 | - |
hcfmusp.relation.reference | Arts B, 2011, ACTA PSYCHIAT SCAND, V123, P190, DOI 10.1111/j.1600-0447.2010.01601.x | - |
hcfmusp.relation.reference | Atmaca M, 2009, INT REV PSYCHIATR, V21, P410, DOI 10.1080/09540260902962206 | - |
hcfmusp.relation.reference | Balanza-Martinez V, 2005, PSYCHOTHER PSYCHOSOM, V74, P113, DOI 10.1159/000083170 | - |
hcfmusp.relation.reference | Balanza-Martinez V, 2010, EUR J PHARMACOL, V626, P87, DOI 10.1016/j.ejphar.2009.10.018 | - |
hcfmusp.relation.reference | Baldessarini RJ, 2000, ARCH GEN PSYCHIAT, V57, P187, DOI 10.1001/archpsyc.57.2.187 | - |
hcfmusp.relation.reference | Bartha L, 2002, CORTEX, V38, P743, DOI 10.1016/S0010-9452(08)70041-8 | - |
hcfmusp.relation.reference | Bearden CE, 2007, BIOL PSYCHIAT, V62, P7, DOI 10.1016/j.biopsych.2006.10.027 | - |
hcfmusp.relation.reference | Berk M, 2011, NEUROSCI BIOBEHAV R, V35, P804, DOI 10.1016/j.neubiorev.2010.10.001 | - |
hcfmusp.relation.reference | Bilik E, 2009, BIPOLAR DISORD, V11, P21 | - |
hcfmusp.relation.reference | Bonnin CM, 2010, J AFFECT DISORDERS, V121, P156, DOI 10.1016/j.jad.2009.05.014 | - |
hcfmusp.relation.reference | Bora E, 2009, J AFFECT DISORDERS, V113, P1, DOI 10.1016/j.jad.2008.06.009 | - |
hcfmusp.relation.reference | Bora E, 2010, J AFFECT DISORDERS, V127, P1, DOI 10.1016/j.jad.2010.02.117 | - |
hcfmusp.relation.reference | Bora E, 2011, ACTA PSYCHIAT SCAND, V123, P165, DOI [10.1111/j.1600-0447.2010.01638.x, 10.1111/j.1369-1600.2010.00266.x] | - |
hcfmusp.relation.reference | Bora E, 2007, BIPOLAR DISORD, V9, P468, DOI 10.1111/j.1399-5618.2007.00469.x | - |
hcfmusp.relation.reference | Bowden CL, 2003, ARCH GEN PSYCHIAT, V60, P392, DOI 10.1001/archpsyc.60.4.392 | - |
hcfmusp.relation.reference | Brown ES, 2001, BIPOLAR DISORD, V3, P23, DOI 10.1034/j.1399-5618.2001.030103.x | - |
hcfmusp.relation.reference | Brumm VL, 1998, NEUROPSY NEUROPSY BE, V11, P245 | - |
hcfmusp.relation.reference | Bubser M, 2012, HDB EXP PHARM, V208, P121 | - |
hcfmusp.relation.reference | Burdick KE, 2010, ACTA PSYCHIAT SCAND, V122, P499, DOI 10.1111/j.1600-0447.2010.01590.x | - |
hcfmusp.relation.reference | Burdick KE, 2011, NEUROPSYCHOPHARMACOL, V36, P1587, DOI 10.1038/npp.2011.36 | - |
hcfmusp.relation.reference | Burt T, 1999, BIOL PSYCHIAT, V45, P959, DOI 10.1016/S0006-3223(98)00320-5 | - |
hcfmusp.relation.reference | Calabrese JR, 2003, J CLIN PSYCHIAT, V64, P1013 | - |
hcfmusp.relation.reference | CALIL HM, 1990, BIOL PSYCHIAT, V27, P711, DOI 10.1016/0006-3223(90)90586-Q | - |
hcfmusp.relation.reference | Castren E, 2010, DEV NEUROBIOL, V70, P289, DOI 10.1002/dneu.20758 | - |
hcfmusp.relation.reference | Chamberlain SR, 2007, J PSYCHOPHARMACOL, V21, P210, DOI 10.1177/0269881107068066 | - |
hcfmusp.relation.reference | Chaves OC, 2011, BIPOLAR DISORD, V13, P118, DOI 10.1111/j.1399-5618.2011.00888.x | - |
hcfmusp.relation.reference | CHRISTODOULOU GN, 1981, AM J PSYCHIAT, V138, P847 | - |
hcfmusp.relation.reference | Daban C, 2006, J CLIN PSYCHOPHARM, V26, P178, DOI 10.1097/01.jcp.0000204332.64390.f3 | - |
hcfmusp.relation.reference | Dias Vasco Videira, 2006, J Psychiatr Pract, V12, P327, DOI 10.1097/00131746-200609000-00010 | - |
hcfmusp.relation.reference | Donaldson S, 2003, J CLIN PSYCHIAT, V64, P86 | - |
hcfmusp.relation.reference | Duffy A, 2009, BMC PSYCHIATRY, V6, P9 | - |
hcfmusp.relation.reference | ELSASS P, 1981, PSYCHOPHARMACOLOGY, V72, P279, DOI 10.1007/BF00431831 | - |
hcfmusp.relation.reference | ENGELSMANN F, 1988, J CLIN PSYCHOPHARM, V8, P207 | - |
hcfmusp.relation.reference | Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044 | - |
hcfmusp.relation.reference | Fountoulakis KN, 2008, INT J NEUROPSYCHOPH, V11, P269, DOI 10.1017/S1461145707007821 | - |
hcfmusp.relation.reference | Fountoulakis KN, 2008, INT J NEUROPSYCHOPH, V11, P999, DOI 10.1017/S1461145708009231 | - |
hcfmusp.relation.reference | Galassi R, 1988, ARCH NEUROL-CHICAGO, V45, P892 | - |
hcfmusp.relation.reference | Geddes JR, 2004, AM J PSYCHIAT, V161, P217, DOI 10.1176/appi.ajp.161.2.217 | - |
hcfmusp.relation.reference | Germana C, 2010, ACTA PSYCHIAT SCAND, V122, P481, DOI 10.1111/j.1600-0447.2010.01582.x | - |
hcfmusp.relation.reference | GHADIRIAN AM, 1983, J CLIN PSYCHOPHARM, V3, P313 | - |
hcfmusp.relation.reference | Ghaemi S Nassir, 2006, J Psychiatr Pract, V12, P300, DOI 10.1097/00131746-200609000-00004 | - |
hcfmusp.relation.reference | Ghaemi SN, 2009, J CLIN PSYCHOPHARM, V29, P291, DOI 10.1097/JCP.0b013e3181a497d7 | - |
hcfmusp.relation.reference | Gildengers AG, 2008, INT J GERIATR PSYCH, V23, P693, DOI 10.1002/gps.1962 | - |
hcfmusp.relation.reference | GILLHAM RA, 1990, EPILEPSY RES, V7, P219, DOI 10.1016/0920-1211(90)90018-Q | - |
hcfmusp.relation.reference | Goldberg JF, 2001, J CLIN PSYCHIAT, V62, P27 | - |
hcfmusp.relation.reference | Goswami U, 2009, ACTA PSYCHIAT SCAND, V120, P456, DOI 10.1111/j.1600-0447.2009.01390.x | - |
hcfmusp.relation.reference | Gualtieri CT, 2006, MEDGENMED, V23, P8 | - |
hcfmusp.relation.reference | Haldane M, 2008, EUR NEUROPSYCHOPHARM, V18, P48, DOI 10.1016/j.euroneuro.2007.05.009 | - |
hcfmusp.relation.reference | HAMILTON MJ, 1993, EPILEPSIA, V34, P166, DOI 10.1111/j.1528-1157.1993.tb02393.x | - |
hcfmusp.relation.reference | Hammonds MD, 2009, BASIC CLIN PHARMACOL, V105, P113, DOI 10.1111/j.1742-7843.2009.00416.x | - |
hcfmusp.relation.reference | Harvey PD, 2007, J CLIN PSYCHIAT, V68, P1186 | - |
hcfmusp.relation.reference | HATCHER S, 1990, BRIT J PSYCHIAT, V157, P275, DOI 10.1192/bjp.157.2.275 | - |
hcfmusp.relation.reference | Hill SK, 2010, EXPERT REV NEUROTHER, V10, P43, DOI [10.1586/ern.09.143, 10.1586/ERN.09.143] | - |
hcfmusp.relation.reference | Honig A, 1999, INT CLIN PSYCHOPHARM, V14, P167, DOI 10.1097/00004850-199905030-00003 | - |
hcfmusp.relation.reference | Ikeda A, 2003, PSYCHIAT CLIN NEUROS, V57, P243, DOI 10.1046/j.1440-1819.2003.01112.x | - |
hcfmusp.relation.reference | Iosifescu DV, 2009, CNS NEUROSCI THER, V15, P309, DOI 10.1111/j.1755-5949.2009.00090.x | - |
hcfmusp.relation.reference | Jacobsen FM, 1999, J CLIN PSYCHIAT, V60, P698 | - |
hcfmusp.relation.reference | James A, 2011, BIPOLAR DISORD, V13, P16, DOI 10.1111/j.1399-5618.2011.00891.x | - |
hcfmusp.relation.reference | Jamrozinski K, 2009, ACTA PSYCHIAT SCAND, V119, P365, DOI 10.1111/j.1600-0447.2008.01320.x | - |
hcfmusp.relation.reference | JAUHAR P, 1993, HUM PSYCHOPHARM CLIN, V8, P141, DOI 10.1002/hup.470080208 | - |
hcfmusp.relation.reference | JOFFE RT, 1988, J CLIN PSYCHOPHARM, V8, P425 | - |
hcfmusp.relation.reference | Kapczinski Flavio, 2009, Expert Rev Neurother, V9, P957, DOI 10.1586/ern.09.31 | - |
hcfmusp.relation.reference | Kapczinski F, 2008, NEUROSCI BIOBEHAV R, V32, P675, DOI 10.1016/j.neubiorev.2007.10.005 | - |
hcfmusp.relation.reference | Kaye NS, 2007, J CLIN PSYCHOPHARM, V27, P387, DOI 10.1097/JCP.0b013e3180a76dd2 | - |
hcfmusp.relation.reference | Keck PE, 2006, J CLIN PSYCHIAT, V67, P19 | - |
hcfmusp.relation.reference | Keefe RSE, 2007, ARCH GEN PSYCHIAT, V64, P633, DOI 10.1001/archpsyc.64.6.633 | - |
hcfmusp.relation.reference | Kelly T, 2008, J AFFECT DISORDERS, V107, P237, DOI 10.1016/j.jad.2007.07.027 | - |
hcfmusp.relation.reference | Kessing LV, 2008, ARCH GEN PSYCHIAT, V65, P1331, DOI 10.1001/archpsyc.65.11.1331 | - |
hcfmusp.relation.reference | Kessing LV, 2010, BIPOLAR DISORD, V12, P87, DOI 10.1111/j.1399-5618.2009.00788.x | - |
hcfmusp.relation.reference | Kessing LV, 2003, J AFFECT DISORDERS, V73, P261, DOI 10.1016/S0165-0327(02)00004-6 | - |
hcfmusp.relation.reference | Ketter Terence A, 2003, Ann Clin Psychiatry, V15, P95, DOI 10.3109/10401230309085675 | - |
hcfmusp.relation.reference | Khan A, 2004, J CLIN PSYCHIAT, V65, P1483 | - |
hcfmusp.relation.reference | KING DJ, 1990, BRIT J PSYCHIAT, V157, P799, DOI 10.1192/bjp.157.6.799 | - |
hcfmusp.relation.reference | KOCSIS JH, 1993, J CLIN PSYCHOPHARM, V13, P268 | - |
hcfmusp.relation.reference | KROPF D, 1985, PHARMACOPSYCHIATRY, V18, P102, DOI 10.1055/s-2007-1017329 | - |
hcfmusp.relation.reference | Kuo CC, 1997, BRIT J PHARMACOL, V121, P1231, DOI 10.1038/sj.bjp.0701221 | - |
hcfmusp.relation.reference | Lagace DC, 2005, PSYCHIAT CLIN N AM, V28, P399, DOI 10.1016/j.psc.2005.02.002 | - |
hcfmusp.relation.reference | LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x | - |
hcfmusp.relation.reference | Lebowitz BK, 2001, NEUROPSY NEUROPSY BE, V14, P177 | - |
hcfmusp.relation.reference | Lee S, 2003, EPILEPSIA, V44, P339, DOI 10.1046/j.1528-1157.2003.27402.x | - |
hcfmusp.relation.reference | Lee SR, 2000, NEUROSCI LETT, V281, P183, DOI 10.1016/S0304-3940(00)00847-8 | - |
hcfmusp.relation.reference | LENZER I, 1989, Clinical Gerontologist, V8, P57 | - |
hcfmusp.relation.reference | Levy B, 2010, J CLIN PSYCHIAT, V71, P201, DOI 10.4088/JCP.08m04663yel | - |
hcfmusp.relation.reference | LINNOILA M, 1986, J CLIN PSYCHOPHARM, V6, P356 | - |
hcfmusp.relation.reference | Lloyd AJ, 2009, ACTA PSYCHIAT SCAND, V120, P481, DOI 10.1111/j.1600-0447.2009.01416.x | - |
hcfmusp.relation.reference | LOO H, 1981, ACTA PSYCHIAT SCAND, V64, P423, DOI 10.1111/j.1600-0447.1981.tb00801.x | - |
hcfmusp.relation.reference | Lopez-Jaramillo C, 2010, J CLIN PSYCHIAT, V71, P1055, DOI 10.4088/JCP.08m04673yel | - |
hcfmusp.relation.reference | Lopez-Jaramillo C, 2010, BIPOLAR DISORD, V12, P557, DOI 10.1111/j.1399-5618.2010.00835.x | - |
hcfmusp.relation.reference | LUND Y, 1982, ACTA PSYCHIAT SCAND, V65, P233, DOI 10.1111/j.1600-0447.1982.tb00843.x | - |
hcfmusp.relation.reference | MacCabe JH, 2010, BRIT J PSYCHIAT, V196, P109, DOI 10.1192/bjp.bp.108.060368 | - |
hcfmusp.relation.reference | Macfadden W, 2009, BIPOLAR DISORD, V11, P827, DOI 10.1111/j.1399-5618.2009.00761.x | - |
hcfmusp.relation.reference | Machado-Vieira R, 2009, BIPOLAR DISORD, V11, P92, DOI 10.1111/j.1399-5618.2009.00714.x | - |
hcfmusp.relation.reference | MacQueen G, 2003, BIPOLAR DISORD, V5, P53, DOI 10.1111/j.1399-2406.2003.00059.x | - |
hcfmusp.relation.reference | Malhi GS, 2009, ACTA PSYCHIAT SCAND, V119, P27, DOI 10.1111/j.1600-0447.2009.01383.x | - |
hcfmusp.relation.reference | Martin R, 1999, NEUROLOGY, V52, P321 | - |
hcfmusp.relation.reference | Martin R, 2001, EPILEPSIA, V42, P764, DOI 10.1046/j.1528-1157.2001.33300.x | - |
hcfmusp.relation.reference | Martinez-Aran A, 2009, J CLIN PSYCHIAT, V70, P1017, DOI 10.4088/JCP.08m04408 | - |
hcfmusp.relation.reference | Martinez-Aran A, 2004, AM J PSYCHIAT, V161, P262, DOI 10.1176/appi.ajp.161.2.262 | - |
hcfmusp.relation.reference | Martinez-Aran A, 2005, PSYCHOTHER PSYCHOSOM, V74, P295, DOI 10.1159/000086320 | - |
hcfmusp.relation.reference | Martinez-Aran A, 2008, J CLIN PSYCHIAT, V69, P233 | - |
hcfmusp.relation.reference | Martinez-Aran A, 2000, PSYCHOTHER PSYCHOSOM, V69, P2, DOI 10.1159/000012361 | - |
hcfmusp.relation.reference | MARUSARZ TZ, 1981, J CLIN PSYCHIAT, V42, P190 | - |
hcfmusp.relation.reference | MEADOR KJ, 1995, NEUROLOGY, V45, P1494 | - |
hcfmusp.relation.reference | Meador KJ, 2001, NEUROLOGY, V56, P1177 | - |
hcfmusp.relation.reference | Meador KJ, 2005, NEUROLOGY, V64, P2108, DOI 10.1212/01.WNL.0000165994.46777.BE | - |
hcfmusp.relation.reference | Meador KJ, 2003, J CLIN PSYCHIAT, V64, P30 | - |
hcfmusp.relation.reference | Michoulas A, 2006, J PEDIATR, V149, P692, DOI 10.1016/j.jpeds.2006.08.015 | - |
hcfmusp.relation.reference | Mohamed K, 2000, SEIZURE-EUR J EPILEP, V9, P137, DOI 10.1053/seiz.2000.0387 | - |
hcfmusp.relation.reference | Moore GJ, 2009, J CLIN PSYCHIAT, V70, P699, DOI 10.4088/JCP.07m03745 | - |
hcfmusp.relation.reference | Mur M, 2008, ACTA PSYCHIAT SCAND, V118, P373, DOI 10.1111/j.1600-0447.2008.01245.x | - |
hcfmusp.relation.reference | National Institute for Health and Clinical Excellence (NICE), 2006, MAN BIP DIS AD CHILD | - |
hcfmusp.relation.reference | Niebauer M, 1999, BRAIN RES, V837, P263, DOI 10.1016/S0006-8993(99)01615-7 | - |
hcfmusp.relation.reference | Nierenberg AA, 2009, PSYCHOTHER PSYCHOSOM, V78, P391, DOI 10.1159/000235985 | - |
hcfmusp.relation.reference | Nivoli AMA, 2010, NEUROPSYCHOBIOLOGY, V62, P27, DOI 10.1159/000314307 | - |
hcfmusp.relation.reference | Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868 | - |
hcfmusp.relation.reference | Pavuluri MN, 2010, BIPOLAR DISORD, V12, P213, DOI 10.1111/j.1399-5618.2010.00792.x | - |
hcfmusp.relation.reference | Quiroz JA, 2010, NEUROPSYCHOBIOLOGY, V62, P50, DOI 10.1159/000314310 | - |
hcfmusp.relation.reference | Ramaekers JG, 1999, J CLIN PSYCHOPHARM, V19, P209, DOI 10.1097/00004714-199906000-00003 | - |
hcfmusp.relation.reference | Ravindran AV, 2008, J CLIN PSYCHIAT, V69, P87 | - |
hcfmusp.relation.reference | Reinares M, 2000, ACTAS ESP PSIQUIATRI, V28, P231 | - |
hcfmusp.relation.reference | Robinson LJ, 2006, BIPOLAR DISORD, V8, P103, DOI 10.1111/j.1399-5618.2006.00277.x | - |
hcfmusp.relation.reference | Rybakowski JK, 2010, INT J NEUROPSYCHOPH, V13, P617, DOI 10.1017/S1461145710000404 | - |
hcfmusp.relation.reference | Saeedi H, 2006, SCHIZOPHR RES, V85, P222, DOI 10.1016/j.schres.2006.03.033 | - |
hcfmusp.relation.reference | Sara SJ, 2009, NAT REV NEUROSCI, V10, P211, DOI 10.1038/nrn2573 | - |
hcfmusp.relation.reference | Savitz J, 2005, BIPOLAR DISORD, V7, P216, DOI 10.1111/j.1399-5618.2005.00203.x | - |
hcfmusp.relation.reference | Schrauwen E, 2006, BIPOLAR DISORD, V8, P196, DOI 10.1111/j.1399-5618.2006.00311.x | - |
hcfmusp.relation.reference | Senturk V, 2007, BIPOLAR DISORD, V9, P136, DOI 10.1111/j.1399-5618.2007.00481.x | - |
hcfmusp.relation.reference | SHARMA I, 1988, INDIAN J MED RES, V88, P246 | - |
hcfmusp.relation.reference | SHAW ED, 1987, J ABNORM PSYCHOL, V96, P64, DOI 10.1037/0021-843X.96.1.64 | - |
hcfmusp.relation.reference | Shi L, 2002, INT J NEUROPSYCHO S1, V5, pS108 | - |
hcfmusp.relation.reference | Siepmann M, 2003, PSYCHOPHARMACOLOGY, V168, P293, DOI 10.1007/s00213-003-1448-4 | - |
hcfmusp.relation.reference | SMIGAN L, 1983, PSYCHOL MED, V13, P529 | - |
hcfmusp.relation.reference | Sole B., 2011, PSYCHOL MED, V28, P1 | - |
hcfmusp.relation.reference | SQUIRE LR, 1980, AM J PSYCHIAT, V137, P1042 | - |
hcfmusp.relation.reference | Stewart SA, 2005, J CLIN PSYCHIAT, V66, P9 | - |
hcfmusp.relation.reference | Stip E, 2000, J AFFECT DISORDERS, V60, P147, DOI 10.1016/S0165-0327(99)00178-0 | - |
hcfmusp.relation.reference | Stoll AL, 1996, J CLIN PSYCHIAT, V57, P356 | - |
hcfmusp.relation.reference | Suwalska A, 2010, NEUROPSYCHOBIOLOGY, V62, P229, DOI 10.1159/000319949 | - |
hcfmusp.relation.reference | Teng CT, 2006, REV BRAS PSIQUIATR, V28, P251 | - |
hcfmusp.relation.reference | Tondo L, 2009, EPIDEMIOL PSICHIAT S, V18, P179 | - |
hcfmusp.relation.reference | Torrent C, 2011, COMPR PSYCHIAT, V52, P613, DOI 10.1016/j.comppsych.2010.12.009 | - |
hcfmusp.relation.reference | Torres IJ, 2010, J CLIN PSYCHIAT, V71, P1234, DOI 10.4088/JCP.08m04997yel | - |
hcfmusp.relation.reference | Torres IJ, 2007, ACTA PSYCHIAT SCAND, V116, P17, DOI 10.1111/j.1600-0447.2007.01055.x | - |
hcfmusp.relation.reference | Tremont G, 1997, PSYCHOPHARMACOL BULL, V33, P273 | - |
hcfmusp.relation.reference | Trojnar MK, 2002, POL J PHARMACOL, V54, P557 | - |
hcfmusp.relation.reference | van Gorp WG, 1998, ARCH GEN PSYCHIAT, V55, P41, DOI 10.1001/archpsyc.55.1.41 | - |
hcfmusp.relation.reference | van Laar MW, 2002, PSYCHOPHARMACOLOGY, V162, P351, DOI 10.1007/s00213-002-1116-0 | - |
hcfmusp.relation.reference | Vieta E, 2009, ACTA PSYCHIAT SCAND, V120, P414, DOI 10.1111/j.1600-0447.2009.01503.x | - |
hcfmusp.relation.reference | Wadsworth EJK, 2005, HUM PSYCHOPHARM CLIN, V20, P561, DOI 10.1002/hup.725 | - |
hcfmusp.relation.reference | Wang SJ, 1996, NEUROREPORT, V7, P3037, DOI 10.1097/00001756-199611250-00048 | - |
hcfmusp.relation.reference | WEINGARTNER H, 1985, PSYCHOPHARMACOLOGY, V86, P472, DOI 10.1007/BF00427911 | - |
hcfmusp.relation.reference | WIARD RP, 1995, STROKE, V26, P466 | - |
hcfmusp.relation.reference | Wingo AP, 2009, J CLIN PSYCHIAT, V70, P1588, DOI 10.4088/JCP.08r04972 | - |
hcfmusp.relation.reference | Yatham LN, 2009, BIPOLAR DISORD, V11, P225, DOI 10.1111/j.1399-5618.2009.00672.x | - |
hcfmusp.relation.reference | Young AH, 2004, NEUROPSYCHOPHARMACOL, V29, P1538, DOI 10.1038/sj.npp.1300471 | - |
hcfmusp.relation.reference | Yurgelun-Todd D, 2002, EUR NEUROPSYCHOPHARM, V12, pS308 | - |
hcfmusp.relation.reference | ZIMMERMANNTANSELLA C, 1984, J CLIN PSYCHOL, V40, P1143, DOI 10.1002/1097-4679(198409)40:5<1143::AID-JCLP2270400504>3.0.CO;2-C | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | AstraZeneca | - |
hcfmusp.remissive.sponsorship | Bayer | - |
hcfmusp.remissive.sponsorship | Bristol-Myers Squibb | - |
hcfmusp.remissive.sponsorship | GlaxoSmithKline | - |
hcfmusp.remissive.sponsorship | Janssen | - |
hcfmusp.remissive.sponsorship | Lilly | - |
hcfmusp.remissive.sponsorship | Lundbeck | - |
hcfmusp.remissive.sponsorship | Merck | - |
hcfmusp.remissive.sponsorship | Novartis | - |
hcfmusp.remissive.sponsorship | Pfizer | - |
hcfmusp.remissive.sponsorship | Sanofi-Aventis | - |
hcfmusp.remissive.sponsorship | Servier | - |
hcfmusp.remissive.sponsorship | Stanley | - |
hcfmusp.remissive.sponsorship | AstraZeneca | - |
hcfmusp.remissive.sponsorship | Bayer | - |
hcfmusp.remissive.sponsorship | Bristol-Myers Squibb | - |
hcfmusp.remissive.sponsorship | GlaxoSmithKline | - |
hcfmusp.remissive.sponsorship | Janssen | - |
hcfmusp.remissive.sponsorship | Johnson and Johnson | - |
hcfmusp.remissive.sponsorship | Lilly | - |
hcfmusp.remissive.sponsorship | Lundbeck | - |
hcfmusp.remissive.sponsorship | Merck | - |
hcfmusp.remissive.sponsorship | Novartis | - |
hcfmusp.remissive.sponsorship | Otsuka | - |
hcfmusp.remissive.sponsorship | Pfizer | - |
hcfmusp.remissive.sponsorship | Sanofi-Aventis | - |
hcfmusp.remissive.sponsorship | Servier | - |
hcfmusp.remissive.sponsorship | Stanley | - |
hcfmusp.lim.ref | 2012 | - |
hcfmusp.citation.scopus | 115 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - LIM/27 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_MACHADO-VIEIRA_Pharmacological_approaches_in_bipolar_disorders_and_the_impact_2012.PDF Restricted Access | publishedVersion (English) | 169.09 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.